Altan Pharma Ltd., an Irish specialty pharma company, has acquired The GES Group, a privately held group that develops, manufactures and markets specialty injectable drugs. GES, headquartered in Spain, is comprised of three operating companies: GES Genéricos Españoles Laboratorio, S.A.U.; Genfarma Laboratorio, S.L. and Biomendi, S.A.U. Financial terms were not disclosed.
 
GES has been providing the Spanish hospital market with a comprehensive line of injectable drugs since 1985. The company is a leading player in the pain and anti-infective segments of the Spanish market and also has an international distribution network covering European, Latin American and Asian markets. The global generic sterile injectables market is projected to grow from $37 billion in 2013 to $70 billion in 2020.
 
“GES is a highly respected leader in the specialty pharmaceutical segment with a reputation for supplying quality, injectable products,” said Guillermo Herrera, chairman and chief executive officer of Altan. “GES’ manufacturing expertise and international distribution network provide an attractive foundation for building Altan’s global specialty pharmaceutical business.”